Monday, June 15, 2026

Satirical Memes Mock South Korea’s President After Martial Law Declaration

Satirical memes mocking President Yoon Suk Yeol's martial law declaration have gone viral, showcasing public discontent and humor.

Luxury Cruise Ship Smuggles Elite SPY Ring US Ally Is COMPROMISED?

The Cruise Dream departs with Chinese tourists under a new visa-free entry system, highlighting streamlined immigration and tourism growth.

K-Culture Craze Fuels New Educational TV Program in Vietnam

A program introducing high schools and universities...

Tag: Wegovy

Wegovy Breaks Records: 3 Million Prescriptions in Just 5 Months – What You Need to Know

Wegovy surpasses 3 million prescriptions in 5 months, marking a significant milestone in the U.S. obesity treatment market.

Teen Prescriptions for GLP-1 Obesity Drugs Surge in Korea, Raising Misuse Concerns

Surge in GLP-1 obesity treatment prescriptions among teens raises concerns over misuse and potential health risks.

Why Are Weight-Loss Drugs So Much Pricier in South Korea?

South Korea faces high obesity treatment costs compared to China and Japan, with no insurance coverage, despite potential patent expirations.

Novo Nordisk’s Oral Wegovy Tops 3,000 Prescriptions in Its First Week—A Challenge to Injectable GLP-1s

Novo Nordisk's Wegovy oral treatment exceeds 3,000 prescriptions in its debut week, signaling a shift towards oral obesity medications.

Novo Nordisk’s Wegovy Pill Draws 3,000 Prescriptions in Its First Week—Is Oral GLP-1 Here to Stay?

Novo Nordisk's Wegovy oral obesity treatment saw over 3,000 prescriptions in its first week, indicating strong market demand.

Wegovy Gets Stronger: New Dose Promises Even More Weight Loss

Novo Nordisk's new high-dose Wegovy aims to enhance obesity treatment, with promising trial results and a strategic EU rollout planned.

Novo Nordisk Pushes for First Oral Obesity Drug Approval

Novo Nordisk seeks FDA approval for oral Wegovy, potentially the first oral obesity treatment, amid competition with Eli Lilly.

Top News

- Our Sponsors Ad -

Follow us